Thursday, 20 Sep 2018

You are here

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.

He cited evidence that falls, narcotic use and advancing age all contribute to imminent risk of fracture incidence. Research on fracture liaison services has shown not only a reduction in mortality but also non-vertebral fracture, and they are cost saving. Falls prevention programmes which prescribe exercise and physical activity can reduce the risk of injury but can be hard to implement.

When considering drug treatment, the options with good evidence include alendronate, riseronate, zolendronic acid, raloxetine, teriparatide and denosumab.

More recently two studies have compared anti-osteoporotic fractures directly. The first was a study comparing risedronate to teriparatide and this showed that teriparatide treated patients treated for 12 and 24 months had substantial decrease in relative rates of fracture. The second study compared romosozumab and alendronate, there were reduced fractures in the romosozumab group.

The next question he addressed was how long should you treat for? Christian points out that the frequency of side effects is low but the patient perception of the frequency of side effects is very high. Studies suggest that the incidence of ONJ is very low at 1-5/10,000 year treatment with anti-resorptive treatment.

Atypical fractures, the risk increases with time, and decreases on discontinuation of treatment. A recent paper quantified the risk after 2 years of treatment is around 2/100,000 cases per year, and after 8 years it rises to 78/100,000 cases per year.

Drug holidays and discontinuing therapy is a hot topic but the amount of evidence is not as great as with the effect of our drugs. One can try to treat to target of T score of -2.5 for example and then discontinue but this is pretty arbitrary target. He did make the point that one needs to be careful in discontinuing some agents, for example denosumab, after discontinuing this it is good to use an anti-resorptive agent to stop the increase in bone resorption.

So, there is an increasing amount of data on the effect of therapeutics but now there are emerging studies on treatment strategies on osteoporosis which will likely guide practice in the future.

Add new comment

More Like This

Osteoarthritis and the Risk of Mortality

Osteoarthritis (OA) affects 27 million Americans but its affect on mortality is uncertain. A recent study shows that while self-reported OA does not increase mortality, radiographic OA of the knee (RKOA) is associated with higher mortality related to CVD, diabetes and renal disease.

2018 EULAR Recommendations for Hand Osteoarthritis Care

The uropean League Against Rheumatism (EULAR) has previously put forth recommendations for management of hand osteoarthritis (OA) in 2007. But since then, advances and further evidence have emerged.

An international panel of 19 physicians, healthcare professionals and patients from 10 European countries formulated five overarching principles and 10 new recommendations after a systematic literature review was performed.

Persistent Osteoporosis Drug Use Pays Off

Among elderly female Medicare patients, persistent use of osteoporosis medications was associated with reduced risk of fracture and significantly lower total health care costs.

Osteoporosis International reports the results of research examining records of 294,369 women >65 years old, on Medicare and taking osteoporosis medicines for the first time at some point between 2009 and 2011. (Citation Source: 

Fractures Augment 10 Year Mortality Risks

This nationwide study of adults (50+ yrs) from Denmark has shown that following a fragility fracture, the 10-years mortality risk was increased, especially in the first year following the fracture. 

Early Hip Fracture Surgery Reduces Mortality

CMAJ reports that seniors are more likely to survive a hip fracture if the surgery is done as soon as they’re admitted to the hospital - suggesting hospitals should expedite operating room access for patients whose surgery has already been delayed for nonmedical reasons. (Citation source: